<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Germline deletions affecting the epithelial cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule (EPCAM) gene lead to silencing of MSH2 and cause <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We have recently reported that lack of EPCAM expression occurs in many, but not <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> from <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> patients with EPCAM germline deletions </plain></SENT>
<SENT sid="2" pm="."><plain>The differences in EPCAM expression were not related to the localization of EPCAM germline deletions </plain></SENT>
<SENT sid="3" pm="."><plain>We therefore hypothesized that the type of the second somatic hit, which leads to MSH2 inactivation during <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> development, determines EPCAM expression in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells </plain></SENT>
<SENT sid="4" pm="."><plain>To test this hypothesis and to evaluate whether lack of EPCAM expression can already be detected in <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e>-associated <z:mpath ids='MPATH_270'>adenomas</z:mpath>, we analyzed four <z:mp ids='MP_0002038'>carcinomas</z:mp> and two <z:mpath ids='MPATH_270'>adenomas</z:mpath> from EPCAM germline deletion carriers for EPCAM protein expression and allelic deletion status of the EPCAM gene region by multiplex ligation-dependent probe amplification </plain></SENT>
<SENT sid="5" pm="."><plain>In four out of six <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> we observed lack of EPCAM expression accompanied by biallelic deletions affecting the EPCAM gene </plain></SENT>
<SENT sid="6" pm="."><plain>In contrast, monoallelic retention of the EPCAM gene was observed in the remaining two <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with retained EPCAM protein expression </plain></SENT>
<SENT sid="7" pm="."><plain>These results demonstrate that EPCAM expression in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> from EPCAM deletion carriers depends on the localization of the second somatic hit that inactivates MSH2 </plain></SENT>
<SENT sid="8" pm="."><plain>Moreover, we report lack of EPCAM protein expression in a colorectal <z:mpath ids='MPATH_270'>adenoma</z:mpath>, suggesting that EPCAM immunohistochemistry may detect EPCAM germline deletions already at a precancerous stage </plain></SENT>
</text></document>